# LianBio

LianBio is an Asset Manager based in Shanghai, China.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Shanghai, China
- **Region:** Asia
- **Address:** Shanghai, China
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** lianbio.com
- **LinkedIn:** https://www.linkedin.com/company/lianbio

## Regulatory record

- **Reports private funds:** No

## About

LianBio is a company founded in 2020 in Shanghai, Shanghai. It focuses on developing medicines for cardiorenal diseases and oncology. LianBio collaborates with partners to advance programs with scientific basis and clinical data.

## Sectors

- Biotechnology
- Pharmaceuticals
- Healthcare Services

## Offices

- Princeton, New Jersey, United States

## People

- Yizhe Wang — Chief Executive Officer
- Deborah Yu — Chief Financial Officer

## Questions

### Which sectors does LianBio explicitly avoid?

LianBio does not publicly disclose excluded sectors, but its disclosed pipeline focuses on cardiovascular, oncology, and inflammatory disease therapeutics — areas with large Asian patient populations and regulatory pathways established by prior approvals.

### Does LianBio participate in fund commitments or only direct deals?

LianBio operates through direct licensing and co-development arrangements with other biotechnology companies. It does not manage external fund commitments; its capital is raised through private equity rounds from institutional investors.

## Related profiles

- [Virbac SA/ADR](https://altss.com/profile/virbac-saadr)
- [Yi Po International Holdings Ltd](https://altss.com/profile/yi-po-international-holdings-ltd)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/lianbio

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology